Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
Johnson and Johnson
McKesson
Moodys

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

RYZODEG 70 Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Ryzodeg 70 patents expire, and what generic alternatives are available?

Ryzodeg 70 is a drug marketed by Novo and is included in one NDA. There are nineteen patents protecting this drug.

The generic ingredient in RYZODEG 70 is insulin aspart; insulin degludec. There are forty drug master file entries for this compound. Additional details are available on the insulin aspart; insulin degludec profile page.

Summary for RYZODEG 70
US Patents:0
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:RYZODEG 70 at DailyMed
Drug patent expirations by year for RYZODEG 70

Notice: You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near ') ORDER BY p.submissiondate DESC' at line 2 in /home/thinkbio/public_html/drugpatentwatch/inc/modules/sm/summary_piv.php on line 32

Warning: mysqli_num_rows() expects parameter 1 to be mysqli_result, boolean given in /home/thinkbio/public_html/drugpatentwatch/inc/modules/sm/summary_piv.php on line 34

US Patents and Regulatory Information for RYZODEG 70

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313-001 Sep 25, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313-001 Sep 25, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313-001 Sep 25, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313-001 Sep 25, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313-001 Sep 25, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
McKesson
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.